13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388551
Total reported value
$1.9M
$1.9M
11 檔
887.9%
According to the latest 13F quarterly dataset, Caxton CORP managed an equity portfolio of $1.9M at the end of Q1 2024, spanning 11 distinct U.S. exchange-listed positions.
In Q1 2024, Caxton CORP adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 4 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 64.38% | — | -9.37% | |
| 2 | RZLT | Rezolute Inc | Stock-Other | 19.16% | — | — | |
| 3 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 5.53% | — | +40.39% | |
| 4 | BRK-B | Berkshire Hathaway Inc-cl B | Stock-Other | 2.44% | +11.69% | -1.55% | |
| 5 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 2.24% | +1.91% | — | |
| 6 | MTEMEUR | Molecular Templates Inc | Stock-Other | 1.75% | — | — | |
| 7 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.56% | — | — | |
| 8 | ABVX | Abivax Sa-adr | Stock-Other | 1.29% | — | -5.58% | |
| 9 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.92% | +2.27% | — | |
| 10 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.49% | — | — | |
| 11 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.23% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RZLT | Rezolute Inc | +12.1% | — | Unchanged |
| 2 | KYTX | Kyverna Therapeutics Inc | +2.2% | NEW | New buy |
| 3 | SPY | Ss Spdr S&p 500 ETF Trust-us | +2.1% | +40.39% | Add |
| 4 | BRD1EUR | Mind Medicine Mindmed Inc | +1.6% | NEW | New buy |
| 5 | BRK-B | Berkshire Hathaway Inc-cl B | +0.5% | -1.55% | Trim |
| 6 | ABVX | Abivax Sa-adr | +0.3% | -5.58% | Trim |
| 7 | TORCEUR | Adicet Bio Inc | +0.2% | NEW | New buy |
| 8 | LXEO | Lexeo Therapeutics Inc | +0.2% | — | Unchanged |
| 9 | CMPX | Compass Therapeutics Inc | +0.1% | — | Unchanged |
| 10 | ALLKGUSD | Allakos Inc | -0.4% | EXIT | Sold out |
| 11 | HARPUSD | Harpoon Therapeutics Inc | -0.7% | EXIT | Sold out |
| 12 | MTEMEUR | Molecular Templates Inc | -1% | — | Unchanged |
| 13 | APGE | Apogee Therapeutics Inc | -1.1% | EXIT | Sold out |
| 14 | XERS | Xeris Biopharma Holdings Inc | -7.2% | -9.37% | Trim |
| 15 | SVRA | Savara Inc | -9% | EXIT | Sold out |
According to official SEC Form 13F filings, Caxton CORP reported a total U.S. public equity portfolio value of $1.9M across 11 disclosed positions in Q1 2024.
During Q1 2024, Caxton CORP's top holdings by market value included XERS (64.4%)、RZLT (19.2%)、SPY (5.5%). The largest single position, XERS, represented 64.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XERS, RZLT, SPY) accounted for 887.9% of total reported equity market value during Q1 2024.
Top New Position Initiated
KYTX
市值: $393.6K
Top Position Liquidated / Trimmed
SVRA
前期市值: $1.7M
In Q1 2024, Caxton CORP made 11 total portfolio adjustments, initiating 3 new buys, adding to 1 positions, trimming 3 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.